Purpose The efficacy and safety of insulin degludec/insulin aspart (IDegAsp) once daily (OD) compared with insulin glargine U100 (IGlar) OD over 52 weeks in insulin-naïve adults with type 2 diabetes mellitus (T2DM) was investigated. Methods In this open-label, parallel-group treat-to-target trial, participants were randomized (1:1) to receive IDegAsp OD (breakfast, n = 266) or ...
-daily pre- or self-mixed insulin. Gregory R. Fulcher,1 Jens Sandahl Christiansen,2 Ganapathi Bantwal,3 Miroslawa Polaszewska Muszynska,4 Henriette Mersebach,5 Thomas H. Andersen,5 and Leo K. Niskanen,6
and Takeda. Henriette Mersebach and Thue Johansen are employed by and own stocks/shares in Novo Nordisk. Stephen Gough has received a research grant and travel costs from Novo Nordisk, and received
OBJECTIVE To evaluate efficacy and tolerability of a co-formulation of insulin degludec and insulin aspart (IDegAsp) with insulin aspart (IAsp) at other meals compared with basal-bolus therapy using insulin detemir (IDet) and IAsp.
TIM HEISE CEES J. TACK ROBERT CUDDIHY JAIME DAVIDSON DIDIER GOUET ANDREAS LIEBL ENRIQUE ROMERO HENRIETTE MERSEBACH PATRIK DYKIEL MSC ROLF JORDE OBJECTIVE-Insulin degludec/insulin aspart (IDegAsp
SIMON HELLER PETER DAMM DMSC HENRIETTE MERSEBACH PHD TRINE VANG SKJTH RISTO KAAJA PHD MOSHE HOD SANTIAGO DUR AN-GARCA PHD DAVID MCCANCE ELISABETH R. MATHIESEN DMSC OBJECTIVE - A recent randomized